Literature DB >> 19843922

Protein kinase A-dependent biophysical phenotype for V227F-KCNJ2 mutation in catecholaminergic polymorphic ventricular tachycardia.

Amanda L Vega1, David J Tester, Michael J Ackerman, Jonathan C Makielski.   

Abstract

BACKGROUND: KCNJ2 encodes Kir2.1, a pore-forming subunit of the cardiac inward rectifier current, I(K1). KCNJ2 mutations are associated with Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia. The aim of this study was to characterize the biophysical and cellular phenotype of a KCNJ2 missense mutation, V227F, found in a patient with catecholaminergic polymorphic ventricular tachycardia. METHODS AND
RESULTS: Kir2.1-wild-type (WT) and V227F channels were expressed individually and together in Cos-1 cells to measure I(K1) by voltage clamp. Unlike typical Andersen-Tawil syndrome-associated KCNJ2 mutations, which show dominant negative loss of function, Kir2.1WT+V227F coexpression yielded I(K1) indistinguishable from Kir2.1-WT under basal conditions. To simulate catecholamine activity, a protein kinase A (PKA)-stimulating cocktail composed of forskolin and 3-isobutyl-1-methylxanthine was used to increase PKA activity. This PKA-simulated catecholaminergic stimulation caused marked reduction of outward I(K1) compared with Kir2.1-WT. PKA-induced reduction in I(K1) was eliminated by mutating the phosphorylation site at serine 425 (S425N).
CONCLUSIONS: Heteromeric Kir2.1-V227F and WT channels showed an unusual latent loss of function biophysical phenotype that depended on PKA-dependent Kir2.1 phosphorylation. This biophysical phenotype, distinct from typical Andersen-Tawil syndrome mutations, suggests a specific mechanism for PKA-dependent I(K1) dysfunction for this KCNJ2 mutation, which correlates with adrenergic conditions underlying the clinical arrhythmia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19843922      PMCID: PMC2766080          DOI: 10.1161/CIRCEP.109.872309

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  36 in total

1.  The consequences of disrupting cardiac inwardly rectifying K(+) current (I(K1)) as revealed by the targeted deletion of the murine Kir2.1 and Kir2.2 genes.

Authors:  J J Zaritsky; J B Redell; B L Tempel; T L Schwarz
Journal:  J Physiol       Date:  2001-06-15       Impact factor: 5.182

2.  Autosomal recessive catecholamine- or exercise-induced polymorphic ventricular tachycardia: clinical features and assignment of the disease gene to chromosome 1p13-21.

Authors:  H Lahat; M Eldar; E Levy-Nissenbaum; T Bahan; E Friedman; A Khoury; A Lorber; D L Kastner; B Goldman; E Pras
Journal:  Circulation       Date:  2001-06-12       Impact factor: 29.690

3.  Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent.

Authors:  R Dumaine; J A Towbin; P Brugada; M Vatta; D V Nesterenko; V V Nesterenko; J Brugada; R Brugada; C Antzelevitch
Journal:  Circ Res       Date:  1999-10-29       Impact factor: 17.367

4.  Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia.

Authors:  Alex V Postma; Isabelle Denjoy; Theo M Hoorntje; Jean-Marc Lupoglazoff; Antoine Da Costa; Pascale Sebillon; Marcel M A M Mannens; Arthur A M Wilde; Pascale Guicheney
Journal:  Circ Res       Date:  2002-10-18       Impact factor: 17.367

5.  Arrhythmogenesis and contractile dysfunction in heart failure: Roles of sodium-calcium exchange, inward rectifier potassium current, and residual beta-adrenergic responsiveness.

Authors:  S M Pogwizd; K Schlotthauer; L Li; W Yuan; D M Bers
Journal:  Circ Res       Date:  2001-06-08       Impact factor: 17.367

6.  A newly characterized SCN5A mutation underlying Brugada syndrome unmasked by hyperthermia.

Authors:  Ngai-Shing Mok; Silvia G Priori; Carlo Napolitano; Ngai-Yin Chan; Mohamed Chahine; Ghayath Baroudi
Journal:  J Cardiovasc Electrophysiol       Date:  2003-04

Review 7.  Andersen-Tawil syndrome: a model of clinical variability, pleiotropy, and genetic heterogeneity.

Authors:  Matthew R Donaldson; Grace Yoon; Ying-Hui Fu; Louis J Ptacek
Journal:  Ann Med       Date:  2004       Impact factor: 4.709

8.  Gastric parietal cell secretory membrane contains PKA- and acid-activated Kir2.1 K+ channels.

Authors:  Danuta H Malinowska; Ann M Sherry; Kirti P Tewari; John Cuppoletti
Journal:  Am J Physiol Cell Physiol       Date:  2003-11-05       Impact factor: 4.249

9.  Fever-induced QTc prolongation and ventricular arrhythmias in individuals with type 2 congenital long QT syndrome.

Authors:  Ahmad S Amin; Lucas J Herfst; Brian P Delisle; Christine A Klemens; Martin B Rook; Connie R Bezzina; Heather A S Underkofler; Katherine M Holzem; Jan M Ruijter; Hanno L Tan; Craig T January; Arthur A M Wilde
Journal:  J Clin Invest       Date:  2008-07       Impact factor: 14.808

10.  Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia.

Authors:  Silvia G Priori; Carlo Napolitano; Mirella Memmi; Barbara Colombi; Fabrizio Drago; Maurizio Gasparini; Luciano DeSimone; Fernando Coltorti; Raffaella Bloise; Roberto Keegan; Fernando E S Cruz Filho; Gabriele Vignati; Abraham Benatar; Angelica DeLogu
Journal:  Circulation       Date:  2002-07-02       Impact factor: 29.690

View more
  25 in total

Review 1.  Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues.

Authors:  Nicole T Feric; Milica Radisic
Journal:  Adv Drug Deliv Rev       Date:  2015-05-05       Impact factor: 15.470

2.  KCNJ2 mutation causes an adrenergic-dependent rectification abnormality with calcium sensitivity and ventricular arrhythmia.

Authors:  Matthew M Kalscheur; Ravi Vaidyanathan; Kate M Orland; Sara Abozeid; Nicholas Fabry; Kathleen R Maginot; Craig T January; Jonathan C Makielski; Lee L Eckhardt
Journal:  Heart Rhythm       Date:  2014-02-21       Impact factor: 6.343

Review 3.  Sinus node dysfunction in catecholaminergic polymorphic ventricular tachycardia: risk factor and potential therapeutic target?

Authors:  Michela Faggioni; Christian van der Werf; Bjorn C Knollmann
Journal:  Trends Cardiovasc Med       Date:  2014-07-10       Impact factor: 6.677

4.  A novel heterozygous mutation in cardiac calsequestrin causes autosomal dominant catecholaminergic polymorphic ventricular tachycardia.

Authors:  Belinda Gray; Richard D Bagnall; Lien Lam; Jodie Ingles; Christian Turner; Eric Haan; Andrew Davis; Pei-Chi Yang; Colleen E Clancy; Raymond W Sy; Christopher Semsarian
Journal:  Heart Rhythm       Date:  2016-05-05       Impact factor: 6.343

Review 5.  Current perspectives in genetic cardiovascular disorders: from basic to clinical aspects.

Authors:  Masa-aki Kawashiri; Kenshi Hayashi; Tetsuo Konno; Noboru Fujino; Hidekazu Ino; Masakazu Yamagishi
Journal:  Heart Vessels       Date:  2013-08-02       Impact factor: 2.037

6.  Altering integrin engagement regulates membrane localization of Kir2.1 channels.

Authors:  Swarnali Sengupta; Katheryn E Rothenberg; Hanjun Li; Brenton D Hoffman; Nenad Bursac
Journal:  J Cell Sci       Date:  2019-09-02       Impact factor: 5.285

7.  Biophysical and molecular characterization of a novel de novo KCNJ2 mutation associated with Andersen-Tawil syndrome and catecholaminergic polymorphic ventricular tachycardia mimicry.

Authors:  Hector Barajas-Martinez; Dan Hu; Gustavo Ontiveros; Gabriel Caceres; Mayurika Desai; Elena Burashnikov; Jorge Scaglione; Charles Antzelevitch
Journal:  Circ Cardiovasc Genet       Date:  2010-12-10

8.  Genetic Loss of IK1 Causes Adrenergic-Induced Phase 3 Early Afterdepolariz ations and Polymorphic and Bidirectional Ventricular Tachycardia.

Authors:  Louise Reilly; Francisco J Alvarado; Di Lang; Sara Abozeid; Hannah Van Ert; Cordell Spellman; Jarrett Warden; Jonathan C Makielski; Alexey V Glukhov; Lee L Eckhardt
Journal:  Circ Arrhythm Electrophysiol       Date:  2020-08-04

Review 9.  Boosting the signal: Endothelial inward rectifier K+ channels.

Authors:  William F Jackson
Journal:  Microcirculation       Date:  2017-04       Impact factor: 2.628

10.  Inhibiting the clathrin-mediated endocytosis pathway rescues K(IR)2.1 downregulation by pentamidine.

Authors:  Rosanne Varkevisser; Marien J C Houtman; Maaike Waasdorp; Joyce C K Man; Raimond Heukers; Hiroki Takanari; Ralph G Tieland; Paul M P van Bergen En Henegouwen; Marc A Vos; Marcel A G van der Heyden
Journal:  Pflugers Arch       Date:  2012-11-29       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.